Dendreon Corp fka DNDNQ

[p3analyze]

Nerd - sounds like proving MOA is not that easy.

From Cancer Vaccines: Moving Beyond Current Paradigms
Jeffrey Schlom, Philip M. Arlen and James L. Gulley

"Several clinical studies have reported statistical correlations between antigen-specific immune responses to vaccine and patient benefit, whereas others have not. These findings may be confounded by several phenomena: (a) the vast majority of studies have examined only T-cell or antibody responses in blood, which may not always correlate with their presence in tumor, and this may vary with tumor size, vasculature, etc.; (b) few studies, if any, have taken into consideration the presence of regulatory T cells and/or have analyzed multiple immune cell subsets (e.g., CD4, CD8, and natural killer responses from a given patient population); (c) virtually all studies have measured the level of antigen-specific T cells, but few studies have monitored avidity of antigen-specific T-cell subsets (51), which is, perhaps, the most important variable to measure; and (d) it has become apparent from preclinical studies that the more important antigen-specific T-cell subsets to monitor may not be those directed to the antigen in the vaccine. As a consequence of initial tumor cell disruption by vaccine-induced cytolytic T cells, cross priming will lead to the generation of T cells directed against other tumor-associated antigens. Preclinical studies (49) have shown that these "antigen cascade" T cells can be of greater magnitude and greater avidity than those directed against the antigen in the vaccine and are those that are principally responsible for tumor cure. Clinical studies (52–54) have also shown this phenomenon of "antigen cascade."

I like the last concluding paragraph
"Skepticism is an important component of the scientific process and it should be an integral component in the development of any potential new therapy. Many are very much aware, for instance, of those skeptics and "naysayers" who, for a decade, dismissed monoclonal antibody–mediated cancer therapy (there are now seven monoclonals approved for cancer management). This too may well be the case for cancer vaccines. Although skepticism is important, there are also those who realize the need for paradigm shifts in both exploiting vaccine combination therapy and analysis of patient benefit in terms of survival (with minimal toxicity) as the appropriate clinical trial end point. "

Do retail shorts/longs all rush to buy those 20 million shares? Don't think so.